Influenza Vaccines - Pandemic threat revitalizes the sector

The influenza vaccine market, sized at approximately $2.2 billion in 2006, yields many challenges. Demand is highly variable, and only large players are able to cope with the need for annual updates and the costly manufacturing process. However, driven by the increasing pandemic threat, the market is growing fast and is predicted to more than double in size by 2016.

Scope of this report

Strategic analysis of the current influenza market across the US, Japan, France, Germany, Italy, Spain and the UK and of key companies in the sector

Thorough assessment of underlying commercial and clinical influencers shaping the influenza vaccine market

Patient-based forecasts for the influenza vaccine market taking into account recommended vaccination groups and coverage rates in the 7 major markets

In-depth comparative analysis of both seasonal and pandemic influenza vaccine pipeline candidates and discussion of their future potential

Research and analysis highlights

The demand for influenza vaccines is highly variable and the time window for the vaccination is limited to just a few months per year. This, in combination with the need for annual updates and the long planning cycles required due to the lengthy egg-based manufacturing process, makes the flu vaccine market a highly challenging sector.

The pandemic threat has acted as an important driver for the seasonal vaccine market. Rising public awareness of influenza has increased the demand for seasonal vaccination. Government funding provided for pandemic research is also benefiting seasonal vaccine development through technology transfer.

With Novartis' cell-based Optaflu currently awaiting EU approval and ProteinSciences' baculovirus-based FluBlØk in phase III, new production techniques available are shaping up to change market dynamics. Further advances include adjuvanted vaccines, and, in earlier development stages, DNA- and universal vaccine candidates.

Key reasons to read this report

Review the clinical and commercial factors driving new product decisions in influenza vaccines and the strategies of key players in the market

Gain insight through a patient-based forecast and a thorough analysis of the seasonal and pandemic influenza vaccine pipeline

Understand where concerns, unmet needs and future opportunities lie by learning about the views of key influenza vaccine opinion leaders

Published: 6 April 2007

PDF Format
Table of Contents
Price: $15,200.00 / GBP8,360.00